Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Neurizon Therapeutics Limited
Entertainment
Neurizon Therapeutics Limited
Messe Düsseldorf (Shanghai) Co., Ltd.
Reolink Innovation Inc.